PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, Japan.\', \'Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.\', \'Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.\', \'Department of Immunology, National Institute of Infectious Diseases, Tokyo, Japan.\', \'International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.\', \'National Virus Reference Laboratory, School of Medicine, University College of Dublin, Dublin, Ireland.\', \'Global Virus Network, Baltimore, MD, USA.\', \'Center for Research and Education On Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.\', \'Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan.\', \'Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Osaka, Japan. akihiko.sato@shionogi.co.jp.\', \'Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan. akihiko.sato@shionogi.co.jp.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-021-84882-7
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 33686154
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
?:title
  • MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all